The Efficacy of Factor VIIa in Emergency Department Patients With Warfarin Use and Traumatic Intracranial Hemorrhage

被引:36
|
作者
Nishijima, Daniel K. [1 ]
Dager, William E. [2 ]
Schrot, Rudolph J. [3 ]
Holmes, James F. [1 ]
机构
[1] UC Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA
[2] UC Davis, Sch Med, Dept Pharm, Davis, CA USA
[3] UC Davis, Sch Med, Dept Neurosurg, Davis, CA USA
关键词
factor VII; traumatic intracranial hemorrhage; warfarin; ACTIVATED FACTOR-VII; RECOMBINANT-FACTOR-VIIA; ACUTE INTRACEREBRAL HEMORRHAGE; INJURY SEVERITY SCORE; BRAIN-INJURY; DOUBLE-BLIND; ANTICOAGULANT-THERAPY; CLINICAL-TRIAL; HEAD-INJURIES; REVERSAL;
D O I
10.1111/j.1553-2712.2010.00666.x
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: The objective was to compare outcomes in emergency department (ED) patients with preinjury warfarin use and traumatic intracranial hemorrhage (tICH) who did and did not receive recombinant activated factor VIIa (rFVIIa) for international normalized ratio (INR) reversal. Methods: This was a retrospective before-and-after study conducted at a Level 1 trauma center, with data from 1999 to 2009. Eligible patients had preinjury warfarin use and tICH on cranial computed tomography (CT) scan. Patients before (standard cohort) and after (rFVIIa cohort) implementation of a protocol for administering 1.2 mg of rFVIIa in the ED were reviewed. Glasgow Coma Scale (GCS) score, Revised Trauma Score (RTS), Injury Severity Score (ISS), INR, and Marshall score were collected. Outcome measures included mortality, thromboembolic complications, and INR normalization. Results: Forty patients (median age = 80.5 years, interquartile range [IQR] = 63.5-85) were included (20 in each cohort). Age, GCS score, ISS, RTS, initial INR, and Marshall score were similar (p > 0.05) between the two cohorts. Survival was identical between cohorts (13 of 20, or 65.0%, 95% confidence interval [CI] = 40.8% to 84.6%). There were no differences in rate of thromboembolic complications in the standard cohort (1 of 20, 5.0%, 95% CI = 0.1% to 24.9%) than the rFVIIa cohort (4 of 20, 20.0%, 95% CI = 5.7% to 43.7%; p = 0.34). Time to normal INR was earlier in the rFVIIa cohort (mean = 4.8 hours, 95% CI = 3.0 to 6.7 hours) than in the standard cohort (mean = 17.5 hours, 95% CI = 12.5 to 22.6; p < 0.001). Conclusions: In patients with preinjury warfarin and tICH, use of rFVIIa was associated with a decreased time to normal INR. However, no difference in mortality was identified. Use of rFVIIa in patients on warfarin and tICH requires further study to demonstrate important patient-oriented outcomes. ACADEMIC EMERGENCY MEDICINE 2010; 17:244-251 (C) 2010 by the Society for Academic Emergency Medicine.
引用
收藏
页码:244 / 251
页数:8
相关论文
共 50 条
  • [1] The Efficacy of Factor VIIa in Emergency Department Patients With Warfarin Use and Traumatic Intracranial Hemorrhage
    Nishyima, D. K.
    Holmes, J. F.
    ANNALS OF EMERGENCY MEDICINE, 2009, 54 (03) : S143 - S143
  • [2] Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage
    David L. Brody
    Venkatesh Aiyagari
    Angela M. Shackleford
    Michael N. Diringer
    Neurocritical Care, 2005, 2 : 263 - 267
  • [3] Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage
    Brody, DL
    Aiyagari, V
    Shackleford, AM
    Diringer, MN
    NEUROCRITICAL CARE, 2005, 2 (03) : 263 - 267
  • [4] Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.
    Diringer, MN
    Aiyagari, V
    Shackleford, AM
    Brody, DL
    BLOOD, 2003, 102 (11) : 109B - 109B
  • [5] Emergency Department Observation of Patients With Traumatic Intracranial Hemorrhage
    Borczuk, P.
    Penn, J.
    Benzer, T.
    Peak, D.
    ANNALS OF EMERGENCY MEDICINE, 2013, 62 (04) : S6 - S7
  • [6] Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage
    S Chou
    X Cai
    R Konigsberg
    L Bresette
    G Henderson
    F Sorond
    A Ropper
    S Feske
    Critical Care, 15 (Suppl 1):
  • [7] Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
    Yampolsky, Natalie
    Stofko, Douglas
    Veznedaroglu, Erol
    Liebman, Kenneth
    Binning, Mandy J.
    SPRINGERPLUS, 2014, 3
  • [8] The use of recombinant factor VIIa in warfarin patients with traumatic brain injury
    DeLoughery, E.
    DeLoughery, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 479 - 480
  • [9] Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage
    Rowe, A. Shaun
    Turner, Ryan M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (05) : 361 - 365
  • [10] Recombinant factor VIIa for rapid reversat of warfarin, anticoagulation in acute intracranial hemorrhage
    Freeman, WD
    Brott, TG
    Barrett, KM
    Castillo, PR
    Deen, HG
    Czervionke, LF
    Meschia, JF
    MAYO CLINIC PROCEEDINGS, 2004, 79 (12) : 1495 - 1500